EyeWorld Korea September 2022 Issue

Refractive and Cataract Workflow months, Dr. Zhang found improved uncorrected distance visual acuity (UDVA) in both dominant and non-dominant eyes and improved uncorrected near visual acuity (UNVA) in dominant and non-dominant eyes. In terms of binocular accommodation function, negative relative accommodation (NRA) and positive relative accommodation (PRA) did not show much difference between preoperative values and postoperative values. Accommodative amplitude (AMP), though, showed an increase preoperatively to postoperatively. For dominant and non-dominant eyes, NRA and PRA values remained similar preoperatively to postoperatively. As for wavefront aberration, spherical aberration values increased preoperatively to postoperatively in both dominant and non-dominant eyes. Within this study, Dr. Zhang also measured satisfaction from patients through a survey. A majority of patients reported that they felt visual recovery was very fast 1 week, 1 month, and 3 months after surgery. Patients also reported having either very good or good visual quality after surgery. When asked if they were satisfied with their decision to undergo surgery with PRESBYOND® LBV, 100% of patients were satisfied at all three follow-up time points. Finally, 100% of patients reported that they would recommend this procedure to their friends and family. Dr. Zhang recommends using PRESBYOND® LBV for patients within the age range of 40 years to 55 years of age. Dr. Zhang did also note the limitations of her study. The patient population was quite small with a short follow-up time. Additionally, most cases included in this study consisted of early-stage presbyopia. Dr. Zhang concluded her presentation with key take-home messages. She emphasized that there may be different kinds of treatment profiles for patients, though not all are universal. Individualization to the patient’s status is still important when managing their presbyopia. Surgeons must understand that none of the current and available solutions will be perfect; patients’ needs are unique and their expectations must be appropriate to their presbyopic situation. At the Forefront of Technology - VISUMAX® 800 and Clinical Outcomes Sri Ganesh, MBBS, MS, India The VISU- MAX® 800 provides ad- vancement in visual technology from the previous VISUMAX 500® with a variety of new features. With the VISUMAX® 800, Sri Ganesh, MBBS, MS, India, explains that the patient bed is completely separated from the machine, allowing for easier adjustment and movement of the patient’s positioning. There is a graphic user interface on the VISUMAX® 800 that can be connected to a variety of diagnostic devices. Patient data can also be imported from these devices to the machine. Another key feature is that the VISUMAX® 800 has two swivel arms: one for the laser and one for the operating microscope. Because the VISUMAX® 800 provides a more efficient workflow with a faster laser, Dr. Ganesh is able to perform more surgeries day-to-day. The ZEISS Refractive Workplace software provides Dr. Ganesh with easier management, evaluation, and storage of data. This software connects to the VISUMAX® 800 so Media placement sponsored by Carl Zeiss Meditec AG Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. The statements of the authors of this supplement reflect only their personal opinion and experience and do not necessarily reflect the opinion of Carl Zeiss Meditec AG or any institution with whom they are affiliated. Carl Zeiss Meditec AG has not necessarily access to clinical data backing the statements of the authors. The statements made by the authors may not yet been scientifically proven and may have to be proven and/or clarified in further clinical studies. Some information presented in this supplement may only be about the current state of clinical research and may not be part of the official product labeling and approved indications of the product. The authors alone are responsible for the content of this supplement and any potential resulting infringements resulting from, in particular, but not alone, copyright, trademark or other intellectual property right infringements as well as unfair competition claims. Carl Zeiss Meditec AG does not accept any responsibility or liability of its content. The VISUMAX® 800 provided excellent stability in terms of spherical equivalent refraction (SEQ) over a time period of 3 months after surgery.

RkJQdWJsaXNoZXIy Njk2NTg0